Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance

Figure 3

Tofa-treated DCs treatment ameliorated EAE. (a) C57BL/6 mice were immunized with peptide emulsified in CFA containing M. tuberculosis. Tofa-treated DCs loaded or unloaded were injected intravenously into mice with EAE on days 7, 11, and 15 after immunization. EAE scores were determined daily after disease onset in the four groups with various treatment conditions. The mean EAE scores ± SEM are shown. The difference was significant at the onset of disease on day 11 and persisted until the chronic phase between the PBS group (vehicle) and Tofa-treated DCs pulsed with group. by ANOVA/Tukey’s post hoc test. In addition, Tofa-treated DCs unpulsed with could not improve disease activity of EAE, similar to that of the PBS group. Results represent the average disease score of eight mice per group. (b) H&E staining and Luxol Fast Blue staining of the paraffin sections of the spinal cords isolated from EAE mice, which were injected with Tofa-treated DCs pulsed or unpulsed with on day 23 after immunization. Arrows indicate inflammatory cell infiltration. Scale bar, 100 μm (magnification 100x).

(a)

(b)